Loading asset research
Oncolytics Biotech Inc. Common Stock
ONCYNasdaq · USD · StocksQuote as of · Exchange session not verified$0.7489
-2.74%
Today
ONCY
Loading 1D prices…
Market cap
$95.1M
Volume
1.2M
52w high
$1.5152w low
$0.73Company profile
Oncolytics Biotech Inc. Common Stock
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (GI) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in San Diego, California.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
San Diego, CA, United States
Employees
29
Fiscal year end
1231
CIK
1129928
Session & valuation
Open$0.77
Previous close$0.77
Day high$0.77
Day low$0.73
30-day avg. volume802.2K
Outstanding shares127.5M
Diluted EPS-$0.30
Latest annual period
P/E (trailing)-2.50
P/E (forward)-3.06
Price / book-15.21
Beta1.15
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| CPIXCumberland Pharmaceuticals Inc. Common Stock | $95.7M | $44.5M | -6.37% | -$0.19 | -1.39% | Unrated |
| ANIXAnixa Biosciences Inc. Common Stock | $95.9M | $0.00 | — | -$0.23 | +1.82% | Buy |
| CTORCitius Oncology Inc. Common Stock | $97M | $7.1M | -577.99% | -$0.42 | +0.88% | Buy |
| PLYXPolaryx Therapeutics Inc. Common Stock | $100.2M | $0.00 | — | -$0.20 | +1.01% | Buy |
| RLYBRallybio Corporation Common Stock | $89.6M | $858K | -1046.39% | -$1.59 | +0.75% | Hold |